Novo Nordisk

Novo Nordisk(NONOF)

BAGSVAERD DENMARK, Denmark
Pharmaceutical1 H-1B visas (FY2023)
WebsiteLinkedInCareers Page

Focus: Regenerative medicine and stem cell therapies

Novo Nordisk is a life sciences company focused on Regenerative medicine and stem cell therapies.

Cell Therapy
Funding Stage
PUBLIC
Open Jobs
0

Products & Portfolio (29)

15 discontinued products not shown

ACTIVELLA
estradiol; norethindrone acetate
LOE Approaching
ORAL · TABLET
characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level. The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. After menopause, most endogenous estrogen is produced by conversion of androstenedione, secreted by the adrenal cortex, to estrone in the peripheral tissues. Thus, estrone and the sulfate-conjugated form, estrone sulfate, are the most abundant circulating estrogens in postmenopausal women. Estrogens act through binding to nuclear receptors in estrogen-responsive tissues. To date, two estrogen receptors have been identified. These vary in proportion from tissue to tissue. Circulating estrogens modulate the pituitary secretion of the gonadotropins, luteinizing hormone (LH), and FSH through a negative feedback mechanism. Estrogens act to reduce the elevated levels of these hormones seen in postmenopausal women. Progestin compounds enhance cellular differentiation and generally oppose the actions of estrogens by decreasing estrogen receptor levels, increasing local metabolism of estrogens to less active metabolites, or inducing gene products that blunt cellular responses to estrogen. Progestins exert their effects in target cells by binding to specific progesterone receptors that interact with progesterone response elements in target genes. Progesterone receptors have been identified in the female reproductive tract, breast, pituitary, hypothalamus, and central nervous system.
a woman with a uterus for: Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause Treatment of Moderate to Severe Symptoms of VulvarVaginal Atrophy due to Menopause Limitations of Use :vaginal atrophy due to menopause+2 more
2006
30
ALHEMO
concizumab
Growth
mAbSubcutaneous · Injectable
Tissue Factor Pathway Inhibitor Antagonists
2024
30
ALHEMO
concizumab
Launch
mAbINJECTION · SOLUTION
Concizumab-mtci is a monoclonal antibody antagonist of endogenous Tissue Factor Pathway Inhibitor (TFPI). Through the inhibition of TFPI, concizumab-mtci acts to enhance FXa production during the initiation phase of coagulation which leads to improved thrombin generation and clot formation with the goal of achieving hemostasis in patients with Hemophilia A or B regardless of their inhibitor status. The effect of concizumab-mtci is not influenced by the presence of inhibitory antibodies to FVIII or FIX. There is no structural relationship or sequence homology between concizumab-mtci and FVIII or FIX and, as such, treatment with concizumab-mtci does not induce or enhance the development of direct inhibitors to FVIII or FIX.
2025
30
FIASP
insulin aspart injection
Peak
INTRAVENOUS, SUBCUTANEOUS · SOLUTION
metabolism. Insulins, including insulin aspart, the active ingredient in FIASP, exert their specific action through binding to insulin receptors. Receptor-bound insulin lowers blood glucose by facilitating cellular uptake of glucose into skeletal muscle and adipose tissue and by inhibiting the output of glucose from the liver. Insulin inhibits lipolysis in the adipocyte, inhibits proteolysis, and enhances protein synthesis.
glycemic control in adult
2017
30
FIASP FLEXTOUCH
insulin aspart injection
Peak
SUBCUTANEOUS · SOLUTION
metabolism. Insulins, including insulin aspart, the active ingredient in FIASP, exert their specific action through binding to insulin receptors. Receptor-bound insulin lowers blood glucose by facilitating cellular uptake of glucose into skeletal muscle and adipose tissue and by inhibiting the output of glucose from the liver. Insulin inhibits lipolysis in the adipocyte, inhibits proteolysis, and enhances protein synthesis.
glycemic control in adult
2017
30
FIASP PENFILL
insulin aspart injection
Peak
SUBCUTANEOUS · SOLUTION
metabolism. Insulins, including insulin aspart, the active ingredient in FIASP, exert their specific action through binding to insulin receptors. Receptor-bound insulin lowers blood glucose by facilitating cellular uptake of glucose into skeletal muscle and adipose tissue and by inhibiting the output of glucose from the liver. Insulin inhibits lipolysis in the adipocyte, inhibits proteolysis, and enhances protein synthesis.
glycemic control in adult
2017
30
LEVEMIR
insulin detemir
LOE Approaching
SUBCUTANEOUS · INJECTABLE
insulin, including LEVEMIR, is regulation of glucose metabolism. Insulins and its analogs lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin also inhibits lipolysis and proteolysis, and enhances protein synthesis.
glycemic control in adult
2005
30
LEVEMIR
insulin detemir
LOE Approaching
INJECTION · INJECTABLE
2005
30
LEVEMIR FLEXTOUCH
insulin detemir
LOE Approaching
SUBCUTANEOUS · INJECTABLE
insulin, including LEVEMIR, is regulation of glucose metabolism. Insulins and its analogs lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin also inhibits lipolysis and proteolysis, and enhances protein synthesis.
glycemic control in adult
2005
30
NORDITROPIN FLEXPRO
somatropin
LOE Approaching
INJECTION · INJECTABLE
cells. This interaction results in intracellular signal transduction and subsequent induction of transcription and translation of GH-dependent proteins including IGF-1, IGF BP-3 and acid-labile subunit. Somatropin has direct tissue and metabolic effects or mediated indirectly by IGF-1, including stimulation of chondrocyte differentiation, and proliferation, stimulation hepatic glucose output, protein synthesis and lipolysis. Somatropin stimulates skeletal growth in pediatric patients with GHD as a result of effects on the growth plates (epiphyses) of long bones. The stimulation of skeletal growth increases linear growth rate (height velocity) in most somatropin-treated pediatric patients. Linear growth is facilitated in part by increased cellular protein synthesis.
• short stature associated with Noonan syndrome• short stature associated with Turner syndrome• short stature born small for gestational age (SGA) with no catch-up growth by age 2 years to 4 years of age+2 more
2000
30
NOVOLIN 70/30
human insulin
LOE Approaching
INJECTION · INJECTABLE
insulin, including NOVOLIN 70/30, is the regulation of glucose metabolism. Insulins lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis, and enhances protein synthesis.
glycemic control in adults
1991
30
NOVOLIN N
human insulin
LOE Approaching
INJECTION · INJECTABLE
insulin, including NOVOLIN N is the regulation of glucose metabolism. Insulins lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis, and enhances protein synthesis.
glycemic control in adults
1991
30
View all 29 products

Pipeline & Clinical Trials

insulin detemir
Diabetes
N/A
Clinical Trials (1)
NCT00771680Observational Study to Evaluate the Effectiveness and Safety of Levemir®, NovoMix® 30 and NovoRapid® in Insulin naïve Subjects With Type 2 Diabetes
N/A
N/A
Clinical Trials (1)
NCT03888157A Research Study Looking at How Victoza® Works in People With Type 2 Diabetes in Iran, Followed in Local Clinical Routine
N/A
insulin detemir
Diabetes
N/A
Clinical Trials (1)
NCT00698269An Observational Study of Efficacy and Safety of Modern Insulin in Diabetes Patients Switched From Anti-diabetic Treatment
N/A
Combining Registry Data in Haemophilia: TARGET H
Haemophilia
N/A
Clinical Trials (1)
NCT03264014Combining Registry Data in Haemophilia: TARGET H
N/A
activated recombinant human factor VII
Congenital Bleeding Disorder
N/A
Clinical Trials (1)
NCT01312636Observational Study on Safety and Efficacy of NovoSeven® in Subjects With Congenital FVII Deficiency
N/A
soluble human insulin
Diabetes
N/A
Clinical Trials (1)
NCT00715780Observational Study to Evaluate Safety and Efficacy of Insulin Therapy in Type 2 Diabetes Mellitus Subjects Failing on Oral Anti-diabetic Agents
N/A
biphasic insulin aspart 30
Diabetes
N/A
Clinical Trials (1)
NCT00699179Observational Study to Evaluate the Efficacy and Safety of NovoMix® 30 in Type 1 and 2 Diabetes
N/A
No treatment given
Haemophilia A
N/A
Clinical Trials (1)
NCT03660774A Study of the Impact of Hemophilia and Its Treatment on Brain Development, Thinking and Behaviour in Children With Hemophilia
N/A
insulin aspart
Diabetes
N/A
Clinical Trials (1)
NCT01487408Special Survey for Type 1 or Type 2 Diabetic Patients
N/A
No treatment given
Obesity
N/A
Clinical Trials (1)
NCT05873660A Study to Characterize the Prevalence of Overweight and Obesity Among Patients With Established Cardiovascular Disease
N/A
No treatment given
Diabetes Mellitus, Type 2
N/A
Clinical Trials (1)
NCT05542420A Research Study, Looking at the Characterization of Treatment Intensified (Add on to Metformin) Real-world Adult Population With Type 2 Diabetes Mellitus in India, Pakistan and Thailand.
N/A
N/A
Clinical Trials (1)
NCT04862923A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in the United Kingdom, as Part of Local Clinical Practice
N/A
Video instruction
Musculoskeletal Disorders
N/A
Clinical Trials (1)
NCT01543893Effect of Personal Versus Video Instruction in Elastic Resistance Exercise on Technical Execution (IRMA05)
N/A
insulin detemir
Diabetes
N/A
Clinical Trials (1)
NCT00706017Observational Study to Evaluate the Safety of Levemir® in Diabetes
N/A
biphasic insulin aspart 30
Diabetes
N/A
Clinical Trials (1)
NCT00737776Observational Study on Efficacy and Safety in Patients Using NovoMix® 30 for the Treatment of Diabetes
N/A
Glucagon infusion
Chronic Kidney Diseases
N/A
Clinical Trials (1)
NCT05056584The Role of the Kidneys and Liver in the Elimination of Glucagon
N/A
N/A
Clinical Trials (1)
NCT06592950Patient Preference Study in Type-2 Diabetes Mellitus: Discrete Choice Experiment (DCE) to Support Novo Nordisk's Long-Acting Insulin
N/A
Evaluating Atherosclerotic Disease Progression in Patients With Diabetes Mellitus
Type 2 Diabetes
N/A
Clinical Trials (1)
NCT07237685Evaluating Atherosclerotic Disease Progression in Patients With Diabetes Mellitus
N/A
insulin aspart
Diabetes
N/A
Clinical Trials (1)
NCT00869908Observational Study on the Effect of NovoMix® 30, Levemir® or NovoRapid® (Alone or Combined) in Type 2 Diabetics Previously Treated With Anti-diabetic Medication
N/A
No treatment given
Obesity
N/A
Clinical Trials (1)
NCT05690789Awareness, Care & Treatment In Obesity Management
N/A
Cardiac Mitochondrial Function After Heart Transplantation
Cardiac Allograft Vasculopathy
N/A
Clinical Trials (1)
NCT04105803Cardiac Mitochondrial Function After Heart Transplantation
N/A
GLP-1 receptor agonist
Type 2 Diabetes
N/A
Clinical Trials (1)
NCT06236672Impact of GLP-1 RAs Compared to Basal Insulin Start in Patients Living With Type 2 Diabetes and Chronic Kidney Disease
N/A
soluble human insulin
Diabetes
N/A
Clinical Trials (1)
NCT00410033Comparison of Antibody Levels in Children and Adolescents After Initiation of Insulin Therapy by Either Insulin Aspart or Soluble Human Insulin
N/A
Growth hormone
Insulin Resistance
N/A
Clinical Trials (1)
NCT00568568Metabolic Studies- Interactions Between GH and Insulin in GHDA
N/A
N/A
Clinical Trials (1)
NCT03631186A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice (SURE SWITZERLAND)
N/A
CH-rich diet with exercise
Type 2 Diabetes
N/A
Clinical Trials (1)
NCT07262788A Feasibility Study of Optimal Non-Pharmacological Lifestyle Modifications in People With Type 2 Diabetes
N/A
Blast Traumatic Brain Injury
Traumatic Brain Injury
N/A
Clinical Trials (1)
NCT01666964Hormone Deficiency After Brain Injury During Combat
N/A
Community-based intervention packages
Obesity
N/A
Clinical Trials (1)
NCT06855563Cities for Better Health Childhood Obesity Prevention Initiative
N/A
Intelligent telemonitoring
Type 2 Diabetes Treated With Insulin
N/A
Clinical Trials (1)
NCT06185296The Intelligent Diabetes TelemonitoRing Using Decision Support to Treat Patients on Insulin Therapy
N/A
insulin detemir
Diabetes
N/A
Clinical Trials (1)
NCT01542476The Impact of Initiating/Switching to Insulin Detemir on Emotional Well-being and Treatment Satisfaction
N/A
Liraglutide
Obesity
N/A
Clinical Trials (1)
NCT03479762In Market Utilisation of Liraglutide Used for Weight Management in the UK: a Study in the CPRD Primary Care Database
N/A
gastric bypass surgery and testing
Gastric Bypass
N/A
Clinical Trials (1)
NCT00915980Meal Stimulating After Roux-en Y Gastric Bypass
N/A
Pedometer intervention
Colorectal Cancer
N/A
Clinical Trials (1)
NCT02522520Pedometer Intervention and Health Effects for Sedentary Colorectal Cancer Patients During Adjuvant Chemotherapy
N/A
N/A
Clinical Trials (1)
NCT05443191A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Finland, as Part of Local Clinical Practice
N/A
Vira mobile app intervention
Mental Health Disorder
N/A
Clinical Trials (1)
NCT05638516Improving Mental Health in Youth and Lowering Risk for Obesity Through a Digital Preventative Product
N/A
N/A
Clinical Trials (1)
NCT04981808Diabetes teleMonitoring of Patients in Insulin Therapy
N/A
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
Hematologic Disorder
N/A
Indocyanine Green
Secondary Lymphedema
N/A
Clinical Trials (1)
NCT03572998Lymphatic Function in Patients Who Have Undergone Breast Cancer Treatment
N/A
No treatment given
Diabetes
N/A
Clinical Trials (1)
NCT01585506Psychosocial Factors Related to Compliance With Treatment With Biphasic Insulin Analogues
N/A
No treatment given
Diabetes
N/A
Clinical Trials (1)
NCT00918151A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Korea
N/A
insulin aspart
Diabetes
N/A
Clinical Trials (1)
NCT00670722Observational Study on Blood Glucose Control in Patients With Diabetes Using Modern Insulin
N/A
insulin detemir
Diabetes
N/A
Clinical Trials (1)
NCT00738153An Observational Study on Efficacy and Safety in Subjects Using Levemir® for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes
N/A
Norditropin
Noonan Syndrome
N/A
Clinical Trials (1)
NCT05308927French Registry of Children Treated With Norditropin® for Short Stature Associated With Noonan Syndrome
N/A
liraglutide
Diabetes
N/A
Clinical Trials (1)
NCT02321878Post-marketing Surveillance (Special Use-results Surveillance) on Use With Liraglutide (Victoza®)
N/A
biphasic insulin aspart 30
Diabetes
N/A
Clinical Trials (1)
NCT00671008Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes
N/A
Needs assesment tool integrated in nursing consultation.
Head and Neck Neoplasms
N/A
Clinical Trials (1)
NCT03443258Needs Assessment Tool Integrated in Clinical Practice of Head and Neck Cancer Rehabilitation
N/A
biphasic insulin aspart 30
Diabetes
N/A
Clinical Trials (1)
NCT01542060Efficacy and Safety of Biphasic Insulin Aspart 30 for the Treatment of Type 2 Diabetes Mellitus
N/A
Continuous Glucose Monitoring
Type 2 Diabetes
N/A
Clinical Trials (1)
NCT06111508The Effect and Safety of a Novel CGM-Based Titration Algorithm for Basal Insulin in T2DM Participants.
N/A
Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive standard diabetes care by their admitting physician
Type 2 Diabetes
N/A
Clinical Trials (1)
NCT00456105The Effect of a Diabetes Action Team in Patients Post Infrainguinal Bypass Surgery With and Without Diabetes
N/A
N/A
Clinical Trials (1)
NCT07302802Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice
N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Founded: 1923
Portfolio: 44 approved products, 149 clinical trials
Top TAs: Metabolic Diseases, Endocrinology, Nephrology
H-1B (2023): 1 approval
Portfolio Health
Launch2 (5%)
Growth2 (5%)
Peak13 (30%)
LOE Approaching26 (59%)
Post-LOE1 (2%)
44 total products
Therapeutic Area Focus
Metabolic Diseases
27 marketed1181 pipeline
Endocrinology
3 marketed56 pipeline
Nephrology
44 pipeline
Cardiovascular
1 marketed41 pipeline
Gastroenterology
42 pipeline
Oncology
28 pipeline
Immunology
25 pipeline
Marketed
Pipeline

Visa Sponsorship

Sponsors Work Visas
H-1B Petitions (FY2023)
1
Approved
0
Denied
100%
Rate

Source: USCIS H-1B Employer Data Hub